Early events marking lung fibroblast transition to profibrotic state in idiopathic pulmonary fibrosis
Author:
Jia Minxue, Rosas Lorena, Kapetanaki Maria G., Tabib Tracy, Sebrat John, Cruz Tamara, Bondonese Anna, Mora Ana L., Lafyatis Robert, Rojas Mauricio, Benos Panayiotis .V.ORCID
Abstract
ABSTRACTBackgroundIdiopathic Pulmonary Fibrosis (IPF) is an age-associated progressive lung disease with accumulation of scar tissue impairing gas exchange. Previous high-throughput studies elucidated the role of cellular heterogeneity and molecular pathways in advanced disease. However, critical pathogenic pathways occurring in the transition of fibroblasts from normal to profibrotic have been largely overlooked.MethodsWe used single cell transcriptomics (scRNA-seq) from lungs of healthy controls and IPF patients (lower and upper lobes). We identified fibroblast subclusters, genes and pathways associated to early disease. Immunofluorescence assays validated the role of MOXD1 early in fibrosis.FindingsWe identified four distinct fibroblast subgroups, including one marking the normal-to-profibrotic state transition. Our results show for the first time that global downregulation of ribosomal proteins and significant upregulation of the majority of copper-binding proteins, including MOXD1, mark the IPF transition. We find no significant differences in gene expression in IPF upper and lower lobe samples, which were selected to have low and high degree of fibrosis, respectively.InterpretationEarly events during IPF onset in fibroblasts include dysregulation of ribosomal and copper-binding proteins. Fibroblasts in early stage IPF have already acquired a profibrotic phenotype while hallmarks of advanced disease, including fibroblast foci and honeycomb formation, are still not evident. The new transitional fibroblasts we discover could prove very important for studying the role of fibroblast plasticity in disease progression and help develop early diagnosis tools and therapeutic interventions targeting earlier disease states.
Publisher
Cold Spring Harbor Laboratory
Reference49 articles.
1. Pathogenesis of Idiopathic Pulmonary Fibrosis 2. Strategies for treating idiopathic pulmonary fibrosis 3. Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis;Front Med (Lausanne),2018 4. Habermann AC , Gutierrez AJ , Bui LT , Yahn SL , Winters NI , Calvi CL , Peter L , Chung M-I , Taylor CJ , Jetter C , Raju L , Roberson J , Ding G , Wood L , Sucre JM , Richmond BW , Serezani AP , McDonnell WJ , Mallal SB , Bacchetta MJ , Loyd JE , Shaver CM , Ware LB , Bremner R , Walia R , Blackwell TS , Banovich NE , Kropski JA . Single-cell RNA-sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. bioRxiv 2019: 753806. 5. McDonough JE , Ahangari F , Li Q , Jain S , Verleden SE , Herazo-Maya J , Vukmirovic M , DeIuliis G , Tzouvelekis A , Tanabe N , Chu F , Yan X , Verschakelen J , Homer RJ , Manatakis DV , Zhang J , Ding J , Maes K , De Sadeleer L , Vos R , Neyrinck A , Benos PV , Bar-Joseph Z , Tantin D , Hogg JC , Vanaudenaerde BM , Wuyts WA , Kaminski N. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight 2019; 4.
|
|